ArticleDiscover oncology2025
A prognostic signature based on insulin-signaling-pathway genes for hepatocellular carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is the most common subtype of liver cancer. HCC occurrence, metastasis and therapeutic effect are closely related to tumor metabolic microenvironment. However, the role of insulin-related glucose metabolism in HCC has also not been extensively studied.
methodTranscriptional profiles and clinical data of HCC samples were retrieved from The Cancer Genome Atlas (TCGA). The insulin signaling pathway related genes were derived from GeneCards and only the protein-coding genes with the top 100 relevance score were retained. Univariate Cox analysis, least absolute shrinkage and selection operator (LASSO) regression analysis and multivariate Cox analysis were conducted to develop the prognosis model. The predictive performance of our prognosis model was assessed by using receiver operating characteristic (ROC) curve, calibration curve and nomogram. Further studies, such as enrichment analysis, drug sensitivity and immunotherapy response were performed to assess the tumor microenvironment and treatment response. The clinical significance of SLC2A1 in HCC was validated with an independent cohort.
resultsWe constructed a prognostic signature based on 4 insulin pathway related genes: RHEB, PRKAA2, SLC2A1 and FOXO1. HCC patients divided into high-risk and low-risk group according to the median risk score. We evaluated the signature in training set, validation set and entire set. The Kaplan-Meier (K-M) survival curve revealed that patients in low-risk group had longer survival. Even in different clinicopathological subgroups, the prognostic signature had good prognostic performance. We also identified that commonly used chemotherapy agents such as 5-fluorouracil, gemcitabine, paclitaxel, sorafenib and sunitinib showed significant sensitivity in the high-risk group. The TIDE algorithm suggested that patients in high-risk group may be more sensitive to immunotherapy. SLC2A1 was selected as the core gene, and the Kaplan-Meier survival curve showed that SLC2A1 positive was significantly associated with prognosis in a HCC independent cohort. Univariate and multivariate Cox analysis demonstrated that SLC2A1 was an independent risk variable for poor prognosis.
conclusionsIn summary, we constructed a prognostic signature based on insulin signaling pathway genes. The excellent performance and applicability of our model underscores its advantages and reliability as a clinical tool. Moreover, we validated SLC2A1 was an independent prognostic factor in a HCC independent cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.